BillionToOne Overview
- Founded
-
2016
- Status
-
Private
- Employees
-
195
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$125M
- Investors
-
34
BillionToOne General Information
Description
Developer of a molecular counter platform intended to upgrade the resolution of cell-free DNA testing. The company's prenatal testing procedure focuses on quantitative biology and statistical learning methods to optimize the signal-to-noise ratio and detect single-gene disorders, enabling expecting mothers to detect disorders such as sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a simple blood test.
Contact Information
Website
www.billiontoone.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Laboratory Services (Healthcare)
Primary Office
- 1035 O'brien Drive
- Suite 1110
- Menlo Park, CA 94025
- United States
+1 (650) 000-0000
BillionToOne Timeline
BillionToOne Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 16-Mar-2022 | $125M | 00000 | 00000 | Completed | Generating Revenue |
| 5. Later Stage VC (Series B) | 14-Jun-2021 | 0000 | 000.00 | 00000 | Completed | Generating Revenue |
| 4. Early Stage VC (Series A) | 22-Feb-2021 | 0000 | 000.00 | 0000 | Completed | Generating Revenue |
| 3. Grant | 01-Jan-2018 | 00000 | 00.00 | Completed | Generating Revenue | |
| 2. Seed Round | 30-Sep-2017 | $2.5M | $2.5M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 22-Aug-2017 | Completed | Startup |
BillionToOne Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 0,000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Series B-2 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series B-1 | 0,000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Series A-6 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series A-5 | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A-4 | 00,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A-3 | 000,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
| Series A-2 | 1,137,210 | $0.000010 | $0.8 | $0.8 | 1x | $0.8 | 2.88% | |
| Series A-1 | 1,349,650 | $0.000010 | $0.4 | $0.4 | 1x | $0.4 | 3.42% |
BillionToOne Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a molecular counter platform intended to upgrade the resolution of cell-free DNA testing. The company's pre
Laboratory Services (Healthcare)
Menlo Park, CA
195
As of 2022
00000
0000
0000-00-00
00000000000
00000
000000
lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
000000000000000000 00000000
San Francisco, CA
0000
As of 0000
00000
000000000
00000
000000
usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
0000000000 00000000 (0000000000)
Gaithersburg, MD
000
As of 0000
0000
0000-00-00
000000&0
Add Comparison
BillionToOne Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Invitae | Formerly VC-backed | San Francisco, CA | 0000 | 00000 | 000000000 | 00000 |
| 000000 | Corporate Backed or Acquired | Gaithersburg, MD | 000 | 000000&0 | ||
| 000000 00000000 | Venture Capital-Backed | San Diego, CA | 00 | 000.00 | 000000000 | 000.00 |
| 000000 | Formerly VC-backed | San Carlos, CA | 0000 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000 | Corporation | Salt Lake City, UT | 0000 | 00000 | 000000 - 000 | 00000 |
BillionToOne Patents
BillionToOne Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220010379-A1 | Non-invasive prenatal testing at early stage of pregnancy | Pending | 07-Jul-2020 | 0000000000 | |
| CA-3123684-A1 | Non-invasive prenatal testing at early stage of pregnancy | Pending | 07-Jul-2020 | 000000000 | |
| EP-3936626-A1 | Non-invasive prenatal testing at early stage of pregnancy | Pending | 07-Jul-2020 | 000000000 | |
| EP-3936626-A4 | Non-invasive prenatal testing at early stage of pregnancy | Pending | 07-Jul-2020 | 000000000 | |
| US-20210292829-A1 | High throughput assays for detecting infectious diseases using capillary electrophoresis | Pending | 23-Mar-2020 | C12Q1/701 |
BillionToOne Executive Team (4)
BillionToOne Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Tsao Ph.D | BillionToOne | Co-Founder, Chief Technology Officer & Board Member | 000 0000 |
| Firat Ileri | Hummingbird Ventures | Board Member | 000 0000 |
| Oguzhan Atay Ph.D | BillionToOne | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
| Swaroop Kolluri | Neotribe Ventures | Board Member | 000 0000 |
| Thomas Bremner | Self | Board Member | 000 0000 |
BillionToOne Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BillionToOne Investors (34)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Adams Street Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Baillie Gifford | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Time BioVentures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| 2c9 Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Four Rivers Group | Venture Capital | Minority | 000 0000 | 000000 0 |